Clinical Trial Update: Evaluation of Monthly Darbepoetin Alfa Dosing for Correction of Anemia in Non-dialysis Chronic Kidney Disease [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating monthly dosing of darbepoetin alfa for correcting anemia in non-dialysis chronic kidney disease has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Chronic Kidney Disease

Drugs mentioned

• ARANESP (DARBEPOETIN ALFA)

Snippet

Sponsor: Amgen | Conditions: Anemia, Chronic Kidney Disease | Phase 3 | Status: COMPLETED | Results posted: 2014-06-04